About
Monoclonal Antibody Treatment for Peripheral Artery Disease
Peles Therapeutics is developing a humanized monoclonal antibody targeting the receptor for advanced glycation end products. With technology in-licensed from Columbia University, the company aims to address the unmet need of peripheral artery disease in diabetic patients using this novel approach.
Identity
| Name | Peles Therapeutics |
|---|---|
| Slug | peles-therapeutics |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkNDc498KDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Aug 2022 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Rehovot |
| HQ address | Rehovot, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
patientstherapeuticsdiabetesdrug-developmentantibodies
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}